ep well ahead estim light top-lin ep guidanc intact
includ celgen opdivo yervoy file lung withdrawn pend os data expect
manag remain upbeat outlook celgen intern forecast
revlimid conserv consensu quantifi
ep estim consensu
ep guidanc exclud celgen reiter last publish
ep includ celgen forma project call
revenu net incom forecast
sale forecast consensu
product beat estim includ orencia sprycel eliqui
emplic reyataz combin ahead forecast product
estim includ opdivo light expect growth atripla/
sustiva yervoy combin forecast baraclud sale
line
gpm estim sg
forecast estim equiti incom
affili lower forecast net incom
estim tax rate forecast sharecount
estim guidanc without celgen revenu
growth mid-singl digit gpm approxim sg decreas mid-singl
digit increas high singl digit tax rate approxim
estim includ celgen compar guidanc
announc morn withdrawn file opdivo yervoy
nsclc high tmb pdufa due recent discuss fda indic
addit data relationship tmb need per
requir final os data part opdivo yervoy opdivo monotherapi vs
chemo patient expect
opdivo yervoy os data part part nsclc
data rcc re-fil eu re-activ
file nsclc-high tmb opdivo data
data gbm opdivo rubraca initi ph tnbc opdivo cabo
data rcc emplic w/abbv ph data mm eu approv r/r
pleas see page report import disclosur
total return/p among highest group eliqui continu grow robustli
still formid player io given opdivo domin posit sever tumor
celgen acquisit bring opportun also risk howev await greater
visibl opdivo competit posit celgen integration/revlimid patent situat
better read io combo
close celgen acquisit
opdivo yervoy os data
nsclc part
non-io pipelin visibl btki ra
psoriasi area
ep compound-annual-growth-rate celgen
revenu compound-annual-growth-rate
better-than-expect data/sal
opdivo io target
greater synergi celgen
competitor gain sale disappoint
fewer synergi celgen
challeng integr
bristol-my squibb compani global biopharmaceut compani lead product
cardiovascular oncolog diabet area among other compani top two
product opdivo eliqui
cowen compani
cowen compani
reportedour estimatedifferenceproduct line cowen
cowen compani
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ continu success exist portfolio notabl eliqui orencia
sprycel baraclud success pipelin product especi nivolumab success
deal patent litig patent expir pressur uncertainti strateg
direct could includ outlook dividend
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
cowen compani llc affili make market stock bristol-my squibb novarti adr roch hold ltd adr secur
cowen compani llc act underwrit announc initi public offer elanco anim health incorpor subsidiari co
cowen compani llc compens research analyst activ servic intend benefit firm investor client individu compens determin research
analyst includ author report base varieti factor includ overal profit firm total revenu deriv sourc includ
revenu invest bank sale trade princip trade revenu cowen compani llc compens research analyst base specif invest
bank transact specif sale trade princip trade revenu
research report simultan avail client client websit research report client research report dissemin e-mail
made avail third-parti aggreg cowen compani llc respons redistribut research third parti aggreg select research report
avail print form addit electron form publish research report obtain firm client websit http //cowenlibrari bluematrix com/client/
inform opinion estim forecast date report subject chang without prior notif seek updat research appropri
variou regul may prevent us research report publish irregular interv appropri analyst judgement
inform subject secur may obtain offic research report publish sole inform purpos constru offer
sell solicit offer buy secur state offer solicit would illeg disclosur relat cowen compani llc
inform herein base sourc believ reliabl guarante us purport complet statement summari avail data
opinion express herein statement judgment date subject chang without notic opinion recommend herein take
account individu client circumst object need intend recommend invest strategi recipi report must make
independ decis regard secur subject research report case secur financi instrument may difficult valu sell reliabl
inform valu risk relat secur financi instrument may difficult obtain extent report discuss legal proceed issu
prepar express intend express legal conclus opinion advic salespeopl trader profession may provid oral written
market commentari trade strategi client reflect opinion contrari opinion express research princip trade area invest
busi may make invest decis inconsist recommend view express research cowen compani llc maintain physic electron
procedur inform barrier address flow inform among depart within cowen compani llc order prevent avoid conflict
interest respect analyst recommend
import disclosur regard compani subject research report pleas contact complianc depart cowen compani llc lexington
